Anti-EGFRvIII antibodies and uses thereof
US11608380B2 · kind B2 · utility
0Cited by
19References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2020 |
| Grant date | Mar 21, 2023 |
| Priority date | — |
| Expiry date | Jul 1, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.